Abstract
Combination with redox modulators can potentiate the anticancer activity and maximize the selectivity of organometallic complexes with redox-based mechanisms of action. We show that nontoxic doses of l-buthionine sulfoximine increase the selectivity of organo-Os complex FY26 for human ovarian cancer cells versus normal lung fibroblasts to 63-fold. This increase is not due to changes in the mechanism of action of FY26 but to the decreased response of cancer cells to oxidative stress.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Antineoplastic Combined Chemotherapy Protocols / chemistry
-
Antineoplastic Combined Chemotherapy Protocols / pharmacology*
-
Apoptosis / drug effects
-
Buthionine Sulfoximine / administration & dosage
-
Cell Cycle / drug effects
-
Cell Line, Tumor / drug effects
-
Cell Proliferation / drug effects
-
Cells, Cultured
-
Coordination Complexes / administration & dosage
-
Coordination Complexes / pharmacology*
-
Female
-
Fibroblasts / drug effects
-
Glutathione / metabolism
-
Humans
-
Membrane Potential, Mitochondrial / drug effects
-
Organometallic Compounds / administration & dosage
-
Organometallic Compounds / pharmacology
-
Osmium / chemistry
-
Osmium / pharmacology
-
Ovarian Neoplasms / drug therapy*
-
Ovarian Neoplasms / metabolism
-
Ovarian Neoplasms / pathology
-
Oxidative Stress / drug effects
-
Reactive Oxygen Species / metabolism
-
Superoxides / metabolism
Substances
-
Coordination Complexes
-
FY26 osmium complex
-
Organometallic Compounds
-
Reactive Oxygen Species
-
Superoxides
-
Osmium
-
Buthionine Sulfoximine
-
Glutathione